BioViva focuses on translating this research into therapies.

In the search to extend human lifespan and address age-related diseases, telomerase reverse transcriptase (TERT) stands out as a promising focus of research. This enzyme, known for its role in maintaining telomeres—the protective caps at the ends of chromosomes—offers potential pathways to combat ageing at a cellular level. BioViva, under the leadership of CEO Liz Parrish, is working to transform telomerase-based scientific breakthroughs into tangible therapies aimed at enhancing health and longevity.